Crossmark

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies

Crossref DOI link: https://doi.org/10.1016/j.reumae.2016.04.015

Published Print: 2017-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Radominski, Sebastião Cezar

Cardiel, Mario Humberto

Citera, Gustavo

Goecke, Annelise

Jaller, Juan Jose

Lomonte, Andrea Barranjard Vannucci

Miranda, Pedro

Velez, Patricia

Xibillé, Daniel

Kwok, Kenneth

Rojo, Ricardo

García, Erika Gabriela
Funding

Funding for this research was provided by:

Pfizer Inc
License Information

Text and Data Mining valid from 2017-07-01
More Information

This article is maintained by: Elsevier

Article Title: Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2016.04.015

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.reuma.2016.04.010

Content Type: article

Copyright: © 2016 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Document is current

Any future updates will be listed below